Hints and tips:
...Ingelheim, after it received approval....
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...Another day, another potential pharmaceuticals deal....
...The first was an €18bn asset swap with Boehringer Ingelheim agreed last December, which, once completed, will see Sanofi trade its animal health unit for the German group’s consumer health business....
...In December 2015, Sanofi entered talks with Boehringer Ingelheim over an €18bn asset exchange that would see the French drugmaker swap its animal health unit for the German company’s consumer health business...
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...Boehringer Ingelheim of Germany filed for information on InterMune’s products. Both rivals were developing similar compounds....
...US regulators also approved stroke-fighting drug Pradaxa for unlisted German pharmaceutical company Boehringer Ingelheim, putting it ahead in its race with rivals Bayer Healthcare and Johnson & Johnson to...
...Since it introduced tough new security measures in 2001, for example, Boehringer Ingelheim of Germany has identified more than 100 incidents of counterfeits of its products, which range from respiratory...
...Abbott had sold Boehringer Ingelheim’s blockbuster arthritis drug Mobic. U.S. pharmaceutical sales fell 21.9 percent....
...Boehringer Ingelheim of Germany already last year developed a product called Spiriva which is marketed by Pfizer in the US, in a blow to Novartis, which has a large respiratory division....
...Ark Therapeutics rose 6.8 per cent to 117p after signing a licensing agreement with Boehringer Ingelheim, the German pharmaceutical company, worth up to €35m....
International Edition